Medicare to pay for Myriad's BRCA testing in prostate cancer patients

By staff writers

July 31, 2020 -- Medicare will be covering use of Myriad's BracAnalysis companion diagnostic in men with prostate cancer who may be eligible for treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza).

Lynparza is approved for patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer. BRCA testing in prostate cancer has been gaining steam with the approval of new indications for Lynparza (Merck/AstraZeneca) and other PARP inhibitors for this tumor type, building on the original approved use for treatment of ovarian cancer.

Experts call for universal genetic testing in metastatic prostate cancer
All men with metastatic prostate cancer or a family history suggesting hereditary risk should be getting genetic testing, experts recommended in an article...
Myriad homes in on CHEK2 carriers' varied breast cancer risk
Myriad Genetics illustrated the wide difference in risk for breast cancer in women who carry CHEK2 mutations in a study presented at the American Society...
FDA clears Myriad's ovarian cancer test
Myriad Genetics has received clearance from the U.S. Food and Drug Administration (FDA) for use of its myChoice CDx test for identifying advanced ovarian...
Myriad files companion BRCA test in prostate cancer
Myriad Genetics' BRACAnalysis companion diagnostic for the drug olaparib (Lynparza) is headed for a new indication in prostate cancer, following the filing...
Lynparza PARP approval opens door to more pancreatic cancer testing
Approval of the drug olaparib (Lynparza, Merck/AstraZeneca) by the U.S. Food and Drug Administration at the end of 2019 paves the way for more testing...

Copyright © 2020

Last Updated ls 7/31/2020 1:05:03 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.